🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Steven Cohen’s CNTX Holdings & Trades

First Buy
Q4 2025
Duration Held
1 Quarters
Largest Add
Q4 2025
+52,701 Shares
Current Position
52,701 Shares
$77,470 Value

Steven Cohen's CNTX Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 52,701 shares of Context Therapeutics Inc. (CNTX) worth $77,470, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Steven Cohen has initiated a new position in CNTX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Context Therapeutics (CNTX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Context Therapeutics (CNTX) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +52,701 New Buy 52,701 $1.47

Steven Cohen's Context Therapeutics Investment FAQs

Steven Cohen first purchased Context Therapeutics Inc. (CNTX) in Q4 2025, acquiring 52,701 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Context Therapeutics Inc. (CNTX) for 1 quarters since Q4 2025.

Steven Cohen's largest addition to Context Therapeutics Inc. (CNTX) was in Q4 2025, adding 52,701 shares worth $77,470.

According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 52,701 shares of Context Therapeutics Inc. (CNTX), valued at approximately $77,470.

As of the Q4 2025 filing, Context Therapeutics Inc. (CNTX) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in Context Therapeutics Inc. (CNTX) was 52,701 shares, as reported at the end of Q4 2025.